Back to top
more

Sarepta Therapeutics (SRPT)

(Real Time Quote from BATS)

$151.27 USD

151.27
36,108

-1.40 (-0.92%)

Updated Jul 16, 2024 10:24 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth A Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (83 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for SRPT

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

2 items in cart

View Cart/Checkout

Sarepta Therapeutics, Inc. [SRPT]

Reports for Purchase

Showing records 381 - 400 ( 667 total )

Company: Sarepta Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 381

12/09/2016

Industry Report

Pages: 6

The Week Ahead in Life Sciences - Upcoming Events for the Week of Dec. 12

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Sarepta Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 382

12/05/2016

Company Report

Pages: 7

Price: 24.95

Company: Sarepta Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 383

11/22/2016

Company Report

Pages: 7

Price: 24.95

Company: Sarepta Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 384

10/27/2016

Company Report

Pages: 6

First Glimpse of Launch Progress Coming in January as Sarepta Reports 3Q16; Reiterate OUTPERFORM

Provider: WEDBUSH SECURITIES INC.

Analyst: BEHANNA H

Price: 25.00

Research Provided by a Third Party

Company: Sarepta Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 385

10/21/2016

Company Report

Pages: 7

Price: 24.95

Company: Sarepta Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 386

10/09/2016

Company Report

Pages: 8

Thinking About the US Launch of Exondys 51; Reiterate OUTPERFORM and Raise PT to $72

Provider: WEDBUSH SECURITIES INC.

Analyst: BEHANNA H

Price: 25.00

Research Provided by a Third Party

Company: Sarepta Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 387

10/09/2016

Company Report

Pages: 7

Sarepta Looks to Bolster its Leading Role in DMD - Inks Deal with Summit; Reiterate OUTPERFORM

Provider: WEDBUSH SECURITIES INC.

Analyst: BEHANNA H

Price: 25.00

Research Provided by a Third Party

Company: Sarepta Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 388

10/04/2016

Company Report

Pages: 7

Sarepta Looks to Bolster its Leading Role in DMD - Inks Deal with Summit; Reiterate OUTPERFORM

Provider: WEDBUSH SECURITIES INC.

Analyst: BEHANNA H

Price: 25.00

Research Provided by a Third Party

Company: Sarepta Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 389

09/20/2016

Daily Note

Pages: 5

The Good News Keeps Coming - Interference Case Means Sarepta Should be Able to Launch Unencumbered in the US; Reiterate OUTPERFORM

Provider: WEDBUSH SECURITIES INC.

Analyst: BEHANNA H

Price: 10.00

Research Provided by a Third Party

Company: Sarepta Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 390

09/20/2016

Company Report

Pages: 6

FDA Finally Gets to YES on Eteplirsen; Reiterate OUTPERFORM and Raise PT to $66

Provider: WEDBUSH SECURITIES INC.

Analyst: BEHANNA H

Price: 25.00

Research Provided by a Third Party

Company: Sarepta Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 391

09/19/2016

Company Report

Pages: 6

Price: 24.95

Company: Sarepta Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 392

08/16/2016

Company Report

Pages: 6

Price: 24.95

Company: Sarepta Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 393

08/01/2016

Industry Report

Pages: 7

PPMD Webinar Gives Parents a DMD Update

Provider: WEDBUSH SECURITIES INC.

Analyst: BEHANNA H

Price: 25.00

Research Provided by a Third Party

Company: Sarepta Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 394

07/19/2016

Company Report

Pages: 6

Sarepta Reports 2Q16 Earnings as We Wait on an Accelerated Approval Decision; Reiterate OUTPERFORM

Provider: WEDBUSH SECURITIES INC.

Analyst: BEHANNA H

Price: 25.00

Research Provided by a Third Party

Company: Sarepta Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 395

07/12/2016

Company Report

Pages: 7

Price: 24.95

Company: Sarepta Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 396

06/24/2016

Industry Report

Pages: 6

The Week Ahead in Life Sciences: Upcoming Events for the Week of June 27

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Sarepta Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 397

06/22/2016

Company Report

Pages: 8

As We Await an FDA Decision on Eteplirsen, Sarepta Looks Forward with Changes to Exon 45/53 Trial Design; Reiterate OUTPERFORM

Provider: WEDBUSH SECURITIES INC.

Analyst: BEHANNA H

Price: 25.00

Research Provided by a Third Party

Company: Sarepta Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 398

06/17/2016

Industry Report

Pages: 6

The Week Ahead in Life Sciences: Upcoming Events for the Week of June 20

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Sarepta Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 399

06/10/2016

Company Report

Pages: 7

Price: 24.95

Company: Sarepta Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 400

06/07/2016

Company Report

Pages: 6

Upgrading to OUTPERFORM; FDA Comes Up with Option "C"; PT to $36

Provider: WEDBUSH SECURITIES INC.

Analyst: BEHANNA H

Price: 25.00

Research Provided by a Third Party